Live Cell High-throughput Screening (LC-HTS) Platform

Our live cell-based high-throughput screening (LC-HTS) platform is used for the identification of innovative antibody drug candidates that bind specifically to the conformational epitopes of novel biomarkers. Using this proprietary technology, we have generated dozens of monoclonal antibodies (mAbs), which are currently in discovery to preclinical stages of development.